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Purpose/Objective: Currently treatment plan evaluation is 
based on the inspection of the calculated dose distributions 
and dose volume histogram (DVH) parameters. The 
robustness with respect to setup uncertainties of the 
treatment plan is not taken into account in the evaluation 
process. Therefore the risk of missing the target or pushing 
dose to critical organs due to setup uncertainties is 
completely unknown. The purpose of this project is to 
develop a tool to assess the robustness of treatment plans 
taking into account random and systematic setup 
uncertainties. 
Materials and Methods: In order to investigate the effect of 
random and systematic setup errors using Monte Carlo (MC) 
methods, the Swiss Monte Carlo Plan (SMCP) [1] was 
extended accordingly. The impact on the dose distributions is 
evaluated by calculating DVHs and dosimetric parameters as 
a function of the setup error phase-space. The evaluation 
tool allows specifying acceptance criteria by means of dose 
deviations from the original dose distribution. Based on these 
robustness-criteria, a robustness-map is generated dividing 
the setup error phase-space into two regions: one for which 
the robustness-criteria are met (acceptance-space) and 
another treatment-plan where the criteria are not fulfilled. A 
treatment-plan is more robust (in terms of the given 
robustness-criteria), compared to another if the acceptance-
space is larger. In addition, deviations for DVHs or dose 
distributions compared to the original plan can be explored 
across the acceptance-space. 
Results: The robustness evaluation tool is demonstrated on 
various cases and different tumor sites. As an example, 
Figure 1 shows the robustness map comparison of a 2 arcs and 
a 4 arcs plan for a head and neck patient using the VMAT 
delivery technique. In this case, the setup uncertainty phase-
space was defined by translations between [-5mm, 5mm] 
along the x- y- and z-axis. The acceptance-space for the 4 
arcs plan is significantly larger, i.e. more robust with respect 
to setup uncertainties. This is due to the fact that with the 4 
arcs plan, a much better sparing of the spinal cord could be 
achieved. 
Figure1: Robustness-map comparison for a head and neck 
treatment plan applying 2 arcs (left) and 4 arcs (right) using 
the VMAT delivery technique. The acceptance-space 
corresponds to the light grey colored area. The 4 arcs plan is 
superior compared to the 2 arcs plan under the given 
acceptance-criteria. 
 
 
Conclusions: The construction and visualization of 
robustness-maps is useful to assess the robustness of RT 
treatment plans. This work is supported by Varian Medical 
Systems. 
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Purpose/Objective:Cervical cancer patients may benefit 
from intensity-modulated proton therapy (IMPT), preferably 
using a patient-specific beam set-up. However, beam set-up 
optimisation is currently not part of the plan optimisation 
process and the influence of the number of beams on dose 
distributions after robustness evaluation is unknown. The aim 
of this study was to develop a method to determine the 
Pareto front (PF) of robust IMPT plans to enable beam set-up 
selection for robust proton therapy planning in cervical 
cancer. 
Materials and Methods: Planning CTs of 3 cervical cancer 
patients treated in prone position with photons were used. 
Per patient, 3 robustly optimised IMPT base plans using 
different beam set-ups were created with a prescribed dose 
of 46 Gy (23 fractions) to the target (CTV). Beam set-ups, 
planning objectives and minimal requirements for evaluation, 
including the evaluation objectives of interest (CTV D99%, 
rectum V30Gy) which span the objective space, are listed 
(Table). For IMPT plans with a fixed beam set-up, only an 
approximation of the real patient-specific PF can be derived 
and an iterative method to approach this PF was written 
using the scripting facilities in RayStation (RaySearch Labs., 
Sweden). Starting with a base plan, multiple plans with new 
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planning objectives, drawn from a Gaussian distribution with 
the base plan objective as mean and a pre-defined standard 
deviation, were automatically generated using worst-case 
scenario optimisation. Plans were evaluated on robustness by 
selecting the single-worst of 12 simulated perturbation 
scenarios based on density (3%) and position (8 mm in all 
directions) errors. For the plans fulfilling all minimal 
requirements after robustness evaluation, the PF was 
estimated based on the dominating plans for which one 
objective of interest cannot be improved without 
deteriorating other evaluation objectives of interest. To 
iteratively improve the PF estimate, a new base plan was 
automatically created using average planning objectives of 
dominating plans for a next iteration. After 5 iterations with 
20 plans each, dominating plans were determined to form the 
2D PF. Per patient, PFs based on different beam set-ups were 
compared by investigating trade-off differences between 
objectives of interest. 
 
Results: In total, 825 robustly optimised IMPT plans were 
automatically created and evaluated within 550 hours. Per 
derived PF, on average 25 plans (range, 11–45) did not fulfil 
all requirements and 15 dominating plans (range, 13–18) were 
found. The figure shows an example of dominating plans that 
form the PF (A) and PFs based on different beam set-ups used 
for comparison (B). For 2 out of 3 patients, PF comparison 
indicated a better trade-off between CTV D99% and rectum 
V30Gy for robust IMPT plans using 4 beams. 
 
 
Conclusions: A novel method to iteratively determine PFs 
based on robustly optimised IMPT plans including robustness 
evaluation was successfully scripted in RayStation. We 
demonstrated the feasibility of beam set-up comparison using 
PFs for proton therapy planning in cervical cancer.  
   
 
 
 
PD-0529   
CT image features associated with patient-rated 
xerostomia after radiotherapy for head and neck cancer 
D. Wagenaar1, A. Van der Schaaf1, N.M. Sijtsema1, L.V. Van 
Dijk1, J.A. Langendijk1, R.J.H.M. Steenbakkers1, C.L. 
Brouwer1 
1University Medical Center Groningen University of 
Groningen, Radiotherapy, Groningen, The Netherlands  
 
Purpose/Objective: Xerostomia is the most frequently 
reported side effect of radiotherapy in head and neck cancer 
and has a major impact on quality of life. Current 
measurements of xerostomia are either subjective or 
unpleasant for the patient. We hypothesize that volume and 
density of the parotid and submandibular glands, which can 
be objectively determined from CT-scans, are related to 
their function and can therefore be used as image biomarkers 
for xerostomia. To test this hypothesis, we investigated the 
association of these image features with patient-rated 
xerostomia. 
Materials and Methods: This prospective study included 110 
patients with head and neck cancer who were treated with 
radiotherapy. Patient-rated xerostomia was scored on a 4-
point Likert scale using the EORTC QLQ-H&N35 questionnaire 
12 weeks after treatment start (Xer12wk) and 6 months after 
treatment (Xer6m). In addition, CT-scans were made at 
baseline and 12 weeks after treatment. The CT density (in 
HU), volume (in cm3) and their change between both CT-
scans were calculated for the parotid and submandibular 
glands. Associations with Xer12wk and Xer6m were calculated 
using univariable and multivariable linear regression and 
Pearson correlation (r). 
Results: In the univariable analysis a statistically significant 
relation was found between Xer12wk and change in volume of 
the parotid glands and change in density of the 
submandibular glands between the CT-scans at baseline and 
12 weeks after treatment (Table 1). Furthermore, a 
statistically significant relation was found between Xer6m and 
change in and density of the parotid glands and change in 
density of the submandibular glands. 
 
 
 
At baseline, a high density of the parotid (β = 0.004, p = 
0.03, r = 0.22) and submandibular glands (β = 0.004, p = 0.05, 
r = 0.20) were predictive for Xer6m. No baseline features were 
significantly associated with Xer12wk. 
In the multivariable model the change in volume of the 
parotid glands and change in density of the submandibular 
